

## GeNeuro announces the end of stabilization operations in connection with IPO and the implementation of a liquidity contract

**Geneva, Switzerland, 4 May 2016** – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), today announced the end of the stabilization operations in connection with its initial public offering on the regulated market of Euronext in Paris and the implementation of a liquidity contract with French broker Gilbert Dupont.

Following the stabilization activities detailed below, the Joint-Lead Managers and Joint-Bookrunners have informed GeNeuro of their intention not to exercise the over-allotment option to subscribe for additional new shares. Consequently, the total number of shares issued by GeNeuro in connection with its IPO remains unchanged at 2,538,500 shares, raising about €33 million.

Pursuant to Article 631-10 of the general regulation of the French *Autorité des Marchés Financiers* (the “AMF”), Bryan, Garnier & Co, acting as stabilization agent, indicated that:

- it has carried out stabilization activities on GeNeuro’s shares ;
- the first stabilization operations started on April 29, 2016 ;
- the last stabilization activity was conducted on May 3, 2016 ;
- stabilization activities have been carried out as follows:

Date	Lowest price (in €)	Highest price (in €)
April 29, 2016	10.29	11.00
May 2, 2016	10.34	11.00
May 3, 2016	11.20	11.20

### Implementation of a liquidity contract

As from May 5, 2016, and for a period of one-year automatically renewable period, GeNeuro has entered into a liquidity contract with French broker Gilbert Dupont that complies with the code of ethics issued by the AMAFI and approved by the French AMF on March 21, 2011.

For the implementation of such contract, €750,000 in cash have been credited to the liquidity account.

### Information available to the public

Copies of the French language prospectus which received a visa from the AMF on 30 March 2016, under no. 16-106 (the “Prospectus”) are available free of charge from GeNeuro’s headquarters (18, chemin des Aulx, CH-1228 Plan-les-Ouates, Geneva, Switzerland) as well as on the websites of the Company ([www.geneuro.com](http://www.geneuro.com)) and of the AMF ([www.amf-france.org](http://www.amf-france.org)).

## Risk factors

GeNeuro draws the public's attention to the risks factors relating to business activities described in chapter 4 "Risk Factors" (and in particular to risk factors mentioned under Section 4.1 "Risks Related to the Products, the Market and the Activity of the Group") in the first part of the Prospectus and in section 2 "Risk Factors Relating to the Offering" in the second part of the Prospectus.

This press release does not constitute an offer of GeNeuro's securities in any other jurisdiction in which such offer is unlawful nor does it constitute a solicitation of an offer to buy GeNeuro's securities in the United States. The securities of GeNeuro may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended (the "Securities Act") or under an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The offer and sale of the securities of GeNeuro has not been and will not be registered under the Securities Act and there will be no public offer of its securities in the United States. This document may not be released, published or distributed, directly or indirectly, in or into Australia, Canada, Japan or the United States.

## Contacts:

### GeNeuro

Jesús Martin-Garcia  
Chairman and CEO  
[investors@geneuro.com](mailto:investors@geneuro.com)  
+41 22 794 50 85

### NewCap

Julien Perez  
Investor relations  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)  
+33 1 44 71 98 52

### NewCap

Nicolas Merigeau  
Media relations  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)  
+33 1 44 71 94 98

## About GeNeuro:

GeNeuro, a spin-off from the Mérieux Institute founded in 2006 with the collaboration of Eclosion and its Eclosion2 fund, is creating a technological platform for the development of new treatments targeting potential causes of neurological disorders and autoimmune diseases such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy and type-1 diabetes.

GeNeuro's first product, GNbAC1, is a monoclonal antibody that neutralises a protein expressed by human endogenous retroviruses, part of the human genome that is normally silent. GeNeuro believes that this drug candidate could become the first treatment addressing a suspected causal factor of multiple sclerosis. GNbAC1 is being developed under a collaboration agreement with Servier.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

## Disclaimer:

This press release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan or the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Canada, Japan or the United States.

No communication and no information in respect of this transaction or of GeNeuro may be distributed to the public in any jurisdiction where a registration or approval is required. No actions have been or will be taken in any jurisdiction (other than France) where such actions would be required. The issue, the subscription for or the purchase of GeNeuro's shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. GeNeuro assumes no responsibility for any violation of any such restrictions by any person.

This press does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003 (the "Prospectus Directive"), as amended, to the extent such Prospectus Directive has been transposed in the relevant Member State of the European Economic Area.

In the United Kingdom, this press release does not constitute an approved prospectus for the purpose of and as defined in section 85 of the Financial Services and Markets Act 2000 (as amended) (the "FSMA").

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.

The distribution of this press release is not made, and has not been approved, by an "authorized person" within the meaning of Article 21(1) of the Financial Services and Markets Act 2000 or any other authority which would be a competent authority for the purposes of the Prospectus Directive.

As a consequence, in the United Kingdom, this press release, insofar as it constitutes an invitation or inducement to participate in the offering, is only being distributed to and only directed at (1) persons who have professional experience in matters related to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or high net worth entities falling within Article 49(2)(a)-(d) of the Order or (2) persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons.

With respect to the Member States of the European Economic Area which have implemented the Prospectus Directive (each a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State, other than France.

For the purposes of this provision, the expression an "offer to the public" in relation to the new or existing shares of the Company in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the new or existing shares of the Company to be offered so as to enable an investor to decide to purchase the new or existing shares of the Company, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State.

The securities referred to herein may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended (the "Securities Act") or another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

**THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.**